Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD

Cynata

Cynata Therapeutics Limited has received approval from UK regulators to start a first-of-its-kind allogeneic IPSC-based trial of MSCs for graft versus host disease (GVHD). Cynata also had some big news a couple weeks back with a deal with Fujifilm. The company is aiming to recruit 16 patients to test whether the MSCs (a type of adult …

Cynata approval for 1st ever allo trial of IPSC-derived MSCs for GVHD Read More »